When was Repertoire Immune Medicines founded?

Repertoire Immune Medicines was founded in 1995 and raised its 1st funding round 22 years after it was founded.

Where is Repertoire Immune Medicines located?

Repertoire Immune Medicines is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

How many employees does Repertoire Immune Medicines have?

As of Jul 31, 2026, the latest employee count at Repertoire Immune Medicines is 82.

Is Repertoire Immune Medicines a funded company?

Repertoire Immune Medicines is a funded company, having raised a total of $298M across 6 funding rounds to date. The company's 1st funding round was a $***** Unattributed round, raised on Nov 14, 2017.

When was the latest funding round of Repertoire Immune Medicines?

Repertoire Immune Medicines' latest funding was a $***** Series B round on Apr 13, 2021, with participation from 5 investors.

Where does Repertoire Immune Medicines rank among its competitors?

Repertoire Immune Medicines ranks 54th amongst 415 active competitors, of which 139 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Biogen, which secured an undisclosed amount in Feb, 2024.

Who are the top competitors of Repertoire Immune Medicines?

Repertoire Immune Medicines' top competitors include Biogen, argenx and Sana Biotechnology. Among them, Biogen secured the most recent funding round in February, 2024.

Repertoire Immune Medicines - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of T-cell-based drugs for the treatment of immune disorders. The company uses DEPLOY and DECODE platforms to design immunotherapeutic. The product pipeline includes PRIME IL-15 a multi-clonal T cell therapeutic candidate activated against a set of tumor-associated antigens, PRIME IL-12 (RPTR 168) designed to provide an effective anti-tumor immune response. The platform generates deep experimental data across cells and thousands of samples and allows them to computationally deduce the most probable path from codes to cures to the knowledge on a population basis.

Website: www.repertoire.com/
Email ID: *****@repertoire.com
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

1995

Location

Cambridge, United States

Stage

Series B

Total Funding

$298M in 6 rounds

Latest Funding Round

Series B, Apr 13, 2021, $*****

Investors

T1D Fund & 6 more

Ranked

54^th among 415 active competitors

Employee Count

82 as on Jul 31, 2026

Similar Companies

Biogen & 485 more

View Repertoire Immune Medicines' full profile

Repertoire Immune Medicines is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
TORQUE THERAPEUTICS, INC CIN: 473334200 , United States, Active	Dec 31, 1999	-	46 (As on Dec 31, 2019)	-

Repertoire Immune Medicines has raised a total funding of $298M over 6 rounds. Its first funding round was on Nov 14, 2017. Its latest funding round was a Series B round on Apr 13, 2021 for $*****. 5 investors participated in its latest round. Repertoire Immune Medicines has 7 institutional investors.

Here is the list of recent funding rounds of Repertoire Immune Medicines:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 13, 2021	1255423	Series B	9939586	3533313	1784925	7636707
Jun 24, 2020	1001996	Grant (prize money)	9537787	3460896	3764414	Covid19 HPC Consortium
Mar 25, 2020	1178346	Unattributed	1056577	9024028	T1D Fund	3114418

Access funding benchmarks and valuations. Sign up today!

View details of Repertoire Immune Medicines's funding rounds and investors

Repertoire Immune Medicines' employee count trend

Repertoire Immune Medicines has 82 employees as of Jul 26. Here is Repertoire Immune Medicines's employee count trend over the years:

Employee count trend for Repertoire Immune Medicines

Uncover Repertoire Immune Medicines' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Repertoire Immune Medicines include Biogen, argenx and Sana Biotechnology. Here is the list of Top 10 competitors of Repertoire Immune Medicines, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
2nd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 20 others	75/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	74/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
5th	Abcellera Biologics 2012, Vancouver (Canada), Public	AI-enabled platform for antibodies discovery	$115M	DCVC, Orbimed & 16 others	71/100
6th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Fidelity Investments & 13 others	71/100
7th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	69/100
8th	Immunocore 2008, Abingdon (United Kingdom), Public	Developer of bispecific T cell receptor therapies for human diseases	$601M	Woodford Investment Management, General Atlantic ... & 50 others	69/100
9th	Nimbus Therapeutics 2009, Cambridge (United States), Series F	Developer of targeted therapeutics for cancer, metabolic and inflammatory diseases	$637M	BVF Partners, Atlas Venture & 20 others	68/100
10th	ADMA Biologics 2005, Ramsey (United States), Public	Biopharmaceutical company innovating plasma-derived therapeutics for immune deficiencies and infectious diseases	$17.6M	Aisling Capital, Burrill and Company & 4 others	68/100
54th	Repertoire Immune Medicines 1995, Cambridge (United States), Series B	Developer of T-cell based drugs for the treatment of immune disorders	$298M	Invus, PSP Investments & 5 others	58/100